profit from every $100 of sales.

electroCore
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
It has no yearly profit to compare the price with.
of earnings would pay off all its debt.
Money in, money out
What electroCore sold, what it kept, and what it did with the cash.
Sales went from $8.59 million in 2022 to $32.0 million in 2025, with -$14.0 million of profit last year.
electroCore vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
electroCore | No profit yet | ||
Boston Scientific | 22.2× · Fair price | ||
Koninklijke Philips | 30.1× · Expensive | ||
Steris | 32.8× · Expensive | ||
Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads electroCore's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 9 | 16 | 25 | 32 | |
| 7 | 13 | 21 | 28 | |
| -23 | -19 | -12 | -13 | |
| -22 | -18 | -10 | -12 | |
| -22 | -19 | -12 | -14 | |
| -4.69 | -3.42 | -1.59 | -1.65 | |
| 81.2% | 82.5% | 85.0% | 86.8% | |
| -266.2% | -120.2% | -48.3% | -41.1% | |
| -257.9% | -117.5% | -47.2% | -43.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 25 | 16 | 20 | 19 |
| Cash | 18 | 10 | 4 | 7 |
| Total debt | 1 | 1 | 4 | 9 |
| Total liabilities | 8 | 9 | 13 | 20 |
| 17 | 7 | 8 | -2 | |
| 5 | 6 | 7 | 8 | |
| -101.6% | -188.7% | -78.4% | -137.3% | |
| -129.7% | -253.1% | -157.6% | 817.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -17 | -15 | -7 | -8 | |
| – | 0 | – | 0 | |
| -17 | -15 | -7 | -8 | |
| Dividends paid | 0 | 0 | – | – |
| – | – | – | – | |
| 3 | 2 | 2 | 2 |
Valuation
- –
- –
- –
- -14.0×
- 1.5×
- –
- –
- -17.0%
- -28.8%
- 0.0%
Profitability
- 86.8%
- -41.1%
- -43.6%
- -38.3%
- -379.1%
- -137.5%
- 836.3%
- -99.4%
- -462.2%
- 8.1%
Growth
- +55.1%
- –
- −18.8%
- –
- +21.1%
Financial health
- –
- -1.67
- 61.3%
- -17.2×
- 1.02
- 0.86
- 2.25
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.59 | -0.59 | +0.0% |
| Mar 19, 2026 | -0.34 | -0.35 | +2.9% |
| Nov 5, 2025 | -0.40 | -0.36 | −11.1% |
| Aug 6, 2025 | -0.35 | -0.32 | −9.4% |
| May 7, 2025 | -0.47 | -0.56 | +16.1% |
| Mar 12, 2025 | -0.40 | -0.34 | −17.6% |
| Nov 13, 2024 | -0.31 | -0.29 | −6.9% |
| Aug 7, 2024 | -0.38 | -0.39 | +2.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about electroCore
Is electroCore a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the electroCore AI analysis
What does electroCore do?
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. It is in Medical - Devices.
Does electroCore pay a dividend?
No. electroCore does not pay a dividend at the moment.
Is electroCore stock halal?
Yes. electroCore passes our halal screen: its business is permitted and its debt is 19% of its market value, under the 30% limit. How we check
How has electroCore stock done over the past year?
Down 8.1% over the past twelve months, to $5.25. It traded between $4.42 and $12.29 and is 57.3% below its high.
Who are electroCore's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with electroCore's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.



